CYPHERPUNK TECHNOLOGIES INC. (CYPH): Nasdaq/NYSE listing notice — Leap Therapeutics receives Nasdaq deficiency notice for low bid price; 180 days to cure

CYPHERPUNK TECHNOLOGIES INC.

Closing bid price below $1.00 for 30 consecutive business days as of March 12, 2025.
Company has until September 8, 2025 to regain compliance by closing at $1.00 for at least 10 consecutive days.
Potential for additional 180-day compliance period if other listing standards met.
Company reviewing options; no assurance of regaining compliance.
Notice is a deficiency, not delisting; shares continue to trade on Nasdaq.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

CYPHERPUNK TECHNOLOGIES INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

f The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). The Closing Bid Price Deficiency Letter is a notice of deficiency, not delisting, and does not currently affect the listing or trading of the Company’s shares of common stock on The Nasdaq Capital Market. The Company has 180 days, or until September 8, 2025, to regain

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

CYPHERPUNK TECHNOLOGIES INC. filing history →

Source: SEC EDGAR

accession 0001104659-25-024450

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.